Prognosis and management of new‐onset atrial fibrillation in critically ill patients

Table 3 Adjusted hazard ratio of 90-day mortality comparing new-onset AF, non-AF and preexisting AF

Outcomes	Group	Hazard ratio	95% CI	p value
90-days mortality
Crude	Non-AF	Ref
	New-onset AF	1.41	1.30–1.52	< 0.001
Model 1	Non-AF	Ref
	New-onset AF	1.33	1.22–1.44	< 0.001
Model 2	Non-AF	Ref
	New-onset AF	1.37	1.26–1.50	< 0.001
Crude	Pre-existing AF	Ref
	New-onset AF	0.81	0.75–0.89	< 0.001
Model 1	Pre-existing AF	Ref
	New-onset AF	1.21	1.11–1.33	< 0.001
Model 2	Pre-existing AF	Ref
	New-onset AF	1.12	1.02–1.23	0.019

Model 1 was adjusted by: age, gender, type of intensive care unit, hypertension, diabetes, coronary heart diseases, congestive heart failure, hyperlipidemia, chronic obstructive pulmonary disease (COPD), cerebral infarction, pulmonary embolism, sepsis, and hypothyroidism; Model 2 was adjusted by: except variables in model 1, the following have been added: Sequential Organ Failure Assessment(SOFA) score, laboratory tests performed on admission, including white blood cells (WBC), hemoglobin (HB), serum creatinine (Scr), and medications during hospitalization, including β blockers, statin, amiodarone, Non-dihydropyridine calcium channel blocker (CCB), digoxin, warfarin
AF atrial fibrillation, Ref reference

ISSN: 1471-2261